Agios Pharmaceuticals, Inc. (AGIO)
$
32.09
+0.25 (0.78%)
Key metrics
Financial statements
Free cash flow per share
-7.0271
Market cap
1.7 Billion
Price to sales ratio
46.6011
Debt to equity
0.0361
Current ratio
18.4970
Income quality
-0.6028
Average inventory
28.6 Million
ROE
0.5031
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing medicines within the realm of cellular metabolism and related biological areas. The company delivers pivotal treatments such as PYRUKYND (mitapivat), an activator for both wild-type and various mutant pyruvate kinase (PK) enzymes targeted at addressing hemolytic anemias. Additionally, Agios is advancing AG-946, currently in Phase I clinical studies for treating hemolytic anemias and other medical indications. Financially, the company earned an interest income of $48,083,000.00 showcasing its strategic financial investments. The income before tax ratio is 19.67 reflecting the pre-tax margin and indicating a robust operational capacity. However, the net total of other income and expenses is $1,143,706,000.00 which illustrates the influence of non-core financial activities on the overall financial picture. Moreover, the company reported depreciation and amortization expenses of $5,653,000.00 which reflect the wear and tear of its physical and intangible assets. The gross profit ratio is 0.89 indicating the efficiency of the company's production and sales operations in maintaining profitability while advancing its innovative drug portfolio. As a notable entity in the biopharmaceutical landscape, Agios Pharmaceuticals operates within a mid-range market capitalization of $1,858,498,768.00 positioning itself as a steady performer in the industry. The stock is affordable at $31.84 making it suitable for budget-conscious investors looking to engage in this sector. Additionally, the stock has an average trading volume of 627,741.00 indicating moderate liquidity, which is essential for investors considering market entry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape and driving forward innovation and growth. Positioned within the Healthcare sector, Agios Pharmaceuticals reflects a commitment to advancing healthcare solutions while fostering economic stability through its strategic investment and operational initiatives.
Is Agios Pharmaceuticals, Inc. (AGIO) a good investment?
Investing in Agios Pharmaceuticals, Inc. (AGIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Agios Pharmaceuticals, Inc. (AGIO)'s stock forecast?
Analysts predict Agios Pharmaceuticals, Inc. stock to fluctuate between $23.42 (low) and $62.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agios Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-30, Agios Pharmaceuticals, Inc.'s market cap is $1,858,498,768, based on 57,915,200 outstanding shares.
How does Agios Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agios Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agios Pharmaceuticals, Inc. (AGIO) stock?
To buy Agios Pharmaceuticals, Inc. (AGIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Agios Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Agios Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $36,498,000 | EPS: $11.86 | Growth: -287.36%.
Where can I find Agios Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.agios.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agios Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Agios Pharmaceuticals, Inc. stock?
All-time high: $62.58 (2024-11-11) | All-time low: $16.75 (2022-06-16).
What are the key trends affecting Agios Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
zacks.com
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
globenewswire.com
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025.
zacks.com
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
zacks.com
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
seekingalpha.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 conference call.
zacks.com
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago.
globenewswire.com
– Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 –
See all news
